| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/25/2009 | EP1287035B1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 03/25/2009 | EP1238282B1 Methods of diagnosis and treatment by binding p75/airm1 |
| 03/25/2009 | EP1221847B1 Methods of enhancing chemotherapy |
| 03/25/2009 | EP0960197B1 GENES FROM 20q13 AMPLICON AND THEIR USES |
| 03/25/2009 | CN101394868A Strong immune induction by using combination of adenovirus type-5/type-35 vector and vaccinia virus mva vector |
| 03/25/2009 | CN101394866A Stabilizer for hydrophobic compounds |
| 03/25/2009 | CN101394845A Extended cycle multiphasic oral contraceptive method |
| 03/25/2009 | CN101391104A New use of oncolytic adenovirus recombinant of tumour cell single-expression immunoloregulation fator GM-CSF |
| 03/25/2009 | CN101391103A Medicine composition for preventing and treating AIDS viral infection |
| 03/25/2009 | CN101390865A Anticancer composition containing lurtolecan |
| 03/25/2009 | CN101390829A Anticancer composition loaded with anti-metabolism medicine fluorouracil and synergist thereof |
| 03/25/2009 | CN101390828A Anticancer composition loaded with anti-metabolism medicine and synergist thereof |
| 03/25/2009 | CN101390827A Sustained-release injection containing methotrexate synergist |
| 03/25/2009 | CN100471502C Composition for cell proliferation |
| 03/25/2009 | CN100471486C Immunomodulatory compositions, methods of making, and methods of use thereof |
| 03/24/2009 | US7507872 Transgenic toll-like receptor 9 (TLR9) mice |
| 03/24/2009 | US7507807 Expression vector comprising nucleotide sequences coding tumor necrosis factor receptor protein (TWEAK) for use in identifying modulators for treatment of inflammatory, cardiovacullar, vision and cancer disorders |
| 03/24/2009 | US7507768 Administering a tablet designed to control moisture containing metformin and glipizide and having a protective coating or finishing layer; glipizide does not hydrolyze and the metformin is compressible; does not have an enteric coating |
| 03/24/2009 | US7507767 Sulfonamide-containing benzene derivatives which exhibit anti-inflammatory and immunodulatory activity |
| 03/24/2009 | US7507759 Methods of using(+)-2-[1-(3-ethoxy-4methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3,-dione |
| 03/24/2009 | US7507715 Administering parathyroid hormone and bone resorption inhibitor; bone disorders |
| 03/24/2009 | US7507707 phosphodiesterase inhibitor; follicle stimulating hormone; clomiphene; anovulation disorder; collecting oocytes for in vitro fertilization; aromatase inhibitor |
| 03/24/2009 | US7507706 Administering a polypeptide to reduce airway hyper responsiveness or reduce the increase of mucus-containing cells in the airway epithelium; IL-13 binding chains of the interleukin-13 receptor |
| 03/24/2009 | US7507705 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 03/24/2009 | US7507542 Autoimmune diseases; inflammatory bowel disease; multiple sclerosis; rheumatic diseases; modulate gene expression |
| 03/24/2009 | US7507540 determining the presence of catalytic antibodies capable of degrading antihemophilic factors in mammals; analyzing the cleavage sites in the antihemophilic factors; biocatalysts; drugs |
| 03/24/2009 | US7507403 drugs comprising an isolated protein, mixed with pharmaceutically acceptable carriers, excipients or diluents, used as an immunogenic composition for stimulating or enhancing the production of antibodies directed against the protein |
| 03/24/2009 | US7507398 Using condensation aerosol (MMAD of less than 5 microns) formed by vaporizing a thin layer of the drug on a solid support and condensing the vapor to treat anxiety, vertigo, alcohol or nicotine withdrawal, sedation, hot flashes, peptic ulcers or for hormone replacement therapy, or pregnancy prevention |
| 03/24/2009 | US7507397 Delivery of muscle relaxants through an inhalation route |
| 03/24/2009 | CA2422380C Pyrazole compounds useful as protein kinase inhibitors |
| 03/24/2009 | CA2407715C Diagnostics and therapeutics for macular degeneration-related disorders |
| 03/24/2009 | CA2390558C Use of polysiloxanes containing quaternary amino groups as formulation auxiliary agents, and agents containing the same |
| 03/24/2009 | CA2377904C Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances |
| 03/24/2009 | CA2345896C A method of modulating ion channel functional activity |
| 03/24/2009 | CA2320717C Method for the treatment of diseases or disorders of the inner ear |
| 03/24/2009 | CA2223513C Betulinic acid derivatives and uses therefor |
| 03/19/2009 | WO2009034325A1 Isoflavone formulation |
| 03/19/2009 | WO2009033293A1 Protein tyrosine phosphatase 1b and cancer |
| 03/19/2009 | WO2009033284A1 Inhibitors of collagen biosynthesis as anti-tumor agents |
| 03/19/2009 | WO2009033282A1 Mitogen-activated protein kinase kinase kinase 14 (map3k14) polymorphisms as indicators of subject outcome in critically ill subjects |
| 03/19/2009 | WO2009033281A1 Cancer combination therapy with a selective inhibitor of histone deacetylase hdac1, hdac2 and/or hdac3 and a microtubule stabilizer |
| 03/19/2009 | WO2009007674A3 Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and ramatroban or seratrodast |
| 03/19/2009 | WO2009007673A3 Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist |
| 03/19/2009 | WO2008147807A3 Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal |
| 03/19/2009 | WO2008143916A3 Prokinetic agent for bowel preparation |
| 03/19/2009 | US20090077681 Methods for Diagnosing and Treating Heart Disease |
| 03/19/2009 | US20090076108 Method for treating obesity |
| 03/19/2009 | US20090076033 Method for treating atherosclerosis employing an aP2 inhibitor and combination |
| 03/19/2009 | US20090076023 Local Anesthetic Methods and Kits |
| 03/19/2009 | US20090075984 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 03/19/2009 | US20090075962 Growth stimulant compositions |
| 03/19/2009 | US20090075951 Methods and Reagents for the Treatment of Inflammatory Disorders |
| 03/19/2009 | US20090075950 Dosage Forms Containing A PPI, NSAID And A Buffer |
| 03/19/2009 | US20090075923 Methods of treatment of renal disease |
| 03/19/2009 | US20090075919 Anti-neoplastic compositions comprising extracts of black cohosh |
| 03/19/2009 | US20090075901 treatment of cell damage caused by ischemia or stroke by administering to a cell or a tissue an effective amount of an isozyme specific delta PKC (protein kinase C) antagonist |
| 03/19/2009 | US20090075873 Gastrin compositions and formulations, and methods of use and preparation |
| 03/19/2009 | US20090075864 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
| 03/19/2009 | US20090075327 Methods for improving secondary metabolite production in fungi |
| 03/19/2009 | US20090074886 Gsk-3 inhibitors |
| 03/19/2009 | US20090074875 Nanoparticulate compositions having lysozyme as a surface stabilizer |
| 03/19/2009 | US20090074870 Alteration of cell membrane for new functions |
| 03/19/2009 | US20090074863 Dosage Forms Containing A PPI, NSAID And A Buffer |
| 03/19/2009 | US20090074847 Transport System In Biological Systems |
| 03/19/2009 | US20090074830 Anti-angiogenic compositions and methods of use |
| 03/19/2009 | US20090074794 for use in the treatment of crohn's and ulcerative colitis; administering a composition comprising an effective amount of at least one isolated mammalian anti-tumor necrosis factor (TNF) antibody comprising at least one variable region comprising SEQ ID NO:7 and 8 |
| 03/19/2009 | US20090074722 Products and methods for treating PTP lar diseases |
| 03/19/2009 | US20090074707 Shaped body and method for production of said body |
| 03/19/2009 | CA2698990A1 Mitogen-activated protein kinase kinase kinase 14 (map3k14) polymorphisms as indicators of subject outcome in critically ill subjects |
| 03/18/2009 | EP2036564A1 The combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist |
| 03/18/2009 | EP2036560A1 (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione for the treatment of benign prostatic hypertrophy |
| 03/18/2009 | EP2036558A2 Orally administrable opioid formulations having extended duration of effect |
| 03/18/2009 | EP2036554A1 Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment for diabetes mellitus |
| 03/18/2009 | EP2036553A1 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| 03/18/2009 | EP2036548A1 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
| 03/18/2009 | EP2035092A2 Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload |
| 03/18/2009 | EP2034992A2 Method of improved diuresis in individuals with impaired renal function |
| 03/18/2009 | EP2034967A1 Oral pharmaceutical composition of a poorly water-soluble active substance |
| 03/18/2009 | EP1448993B1 Detection of autoantibodies reactive with pancreatic islet cell antigenic molecules |
| 03/18/2009 | EP1389096B1 Delivery of opioids through an inhalation route |
| 03/18/2009 | EP1353624B1 Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| 03/18/2009 | EP1292316B1 Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use |
| 03/18/2009 | EP1292294B1 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease |
| 03/18/2009 | EP1280420B9 Natural vegetable oil concentrated in unsaponifiable matters as food ingredient |
| 03/18/2009 | EP1231877A4 Transdermal administration of huperzine |
| 03/18/2009 | EP1218498B1 Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
| 03/18/2009 | EP1146789B1 Treating cancers associated with overexpression of her-2/neu |
| 03/18/2009 | EP1095136B1 Cells and animals deficient in protein kinase c epsilon |
| 03/18/2009 | EP1077678A4 Mucoadhesive compositions for administration of biologically active agents to animal tissue |
| 03/18/2009 | EP1030929B1 Transfection and transfer of non-human male germ cells for generation of transgenic non-human mammals |
| 03/18/2009 | EP0979090B1 Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine |
| 03/18/2009 | EP0975954B2 Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules |
| 03/18/2009 | CN101389352A Agent for treating or preventing digestive ulcer |
| 03/18/2009 | CN101389345A Combinatorial methods and compositions for treatment of melanoma. |
| 03/18/2009 | CN101389340A Combinations of steroids and methylxanthine compounds |
| 03/18/2009 | CN101389339A Therapeutic agent for diabetes |
| 03/18/2009 | CN101387646A Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b |
| 03/18/2009 | CN101385738A Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside |
| 03/18/2009 | CN101385723A Association between an anti-atherothrombotic and an angiotensin conversion enzyme inhibitor |
| 03/18/2009 | CN101385718A Osmotic pump preparation composition for treating hyperlipemia |